Left Bundle Branch Area Pacing in Heart Failure Patients With Ejection Fraction Below Normal
Recruiting now
Conditions studied: Left Ventricular Ejection Fraction Less Then or Equal to 50percent
In brief
While cardiac resynchronization therapy remains the mainstay for advanced HF, it is not always feasible due to unfavorable anatomy of coronary sinus or pacing characteristics. In such cases, left bundle branch area pacing itself or left bundle optimized cardiac resynchronization therapy could be a rescue therapy for failed or unsuccessful biventricular cardiac resynchronization therapy. However, the efficacy and safety of left bundle branch area pacing (or left bundle optimized cardiac resynchronization therapy) as rescue therapy for biventricular cardiac resynchronization therapy is largely hypothetic and lack concrete evidence still. Therefore, there is an unmet need for the registry purposed for left bundle branch area pacing among heart failure with mid-range (or mildly reduced) ejection fraction and heart failure with reduced ejection fraction patients to investigate its efficacy and safety. This study aims to investigate the efficacy and safety of left bundle branch area pacing in heart failure patients with ejection fraction below normal using Selectra catheters.
Key facts
- Study ID
- NCT06148571
- Run by
- Seoul National University Hospital
- People needed
- 200
- Starts
- 2023-10-10
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-05-19
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients previously diagnosed with heart failure with mid-range(or mildly reduced) ejection fraction and heart failure with reduced ejection fraction, which was documented by an appropriate echocardiographic study (Left ventricle ejection fraction <50%), and
- Patients with indications of cardiac pacing or cardiac resynchronization therapy
You may not qualify if…
- Patients aged less than 19 years.
- Pregnant.
- Patients with an expected life expectancy of less than 1 year.
- Patients with a mechanical valve for the tricuspid valve.
- Patients who need atrial pacing only.
- Patients who are not capable of receiving a transvenous pacemaker for any reason.
Where it is running
- Seoul National University Hospital — Seoul, Jongno-gu, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.